Patents Assigned to AC Immune S.A.
  • HUMANIZED ANTIBODY
    Publication number: 20220227847
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: August 4, 2021
    Publication date: July 21, 2022
    Applicants: AC Immune S.A., Genentech, Inc.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • HUMANIZED ANTIBODY
    Publication number: 20210317197
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: November 16, 2020
    Publication date: October 14, 2021
    Applicants: AC Immune S.A., Genentech, Inc.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Compounds for imaging Tau protein aggregates
    Patent number: 10865207
    Abstract: The present invention relates to novel compounds of the formula (I) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: December 15, 2020
    Assignees: AC IMMUNE S.A., LIFE MOLECULAR IMAGING SA
    Inventors: Heiko Kroth, Jérôme Molette, Hanno Schieferstein, Andre Müller, Heribert Schmitt-Willich, Mathias Berndt, Felix Oden
  • Compounds for imaging Tau protein aggregates
    Patent number: 10835624
    Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: November 17, 2020
    Assignees: AC IMMUNE S.A., LIFE MOLECULAR IMAGING SA
    Inventors: Heiko Kroth, Jérôme Molette, Vincent Darmency, Hanno Schieferstein, Andre Müller, Heribert Schmitt-Willich, Mathias Berndt, Felix Oden, Emanuele Gabellieri
  • HUMANIZED ANTIBODY
    Publication number: 20200055928
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: April 1, 2019
    Publication date: February 20, 2020
    Applicants: AC Immune S.A., Genentech, Inc.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • HUMANIZED ANTIBODY IGG1
    Publication number: 20190031746
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: February 22, 2018
    Publication date: January 31, 2019
    Applicants: AC Immune S.A., Genentech, Inc.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • HUMANIZED ANTIBODY
    Publication number: 20180327485
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: December 4, 2017
    Publication date: November 15, 2018
    Applicants: AC Immune S.A., Genentech, Inc.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Methods of diagnosing tau-protein-associated disease
    Patent number: 10100104
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: October 16, 2018
    Assignees: KATHOLIEKE UNIVERSITEIT LEUVEN, AC IMMUNE S.A.
    Inventors: Andrea Pfeifer, Andreas Muhs, Fred Van Leuven, Maria Pihlgren, Oskar Adolfsson
  • NOVEL IMAGING COMPOUNDS
    Publication number: 20180264146
    Abstract: The present invention relates to novel compounds that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: July 15, 2016
    Publication date: September 20, 2018
    Applicants: AC IMMUNE S.A., PIRAMAL IMAGING SA
    Inventors: Heiko KROTH, Sreenivasachary NAMPALLY, Jérôme MOLETTE, Emanuele GABELLIERI, Hanno SCHIEFERSTEIN, Andre MÜLLER, Heribert SCHMITT-WILLICH, Mathias BERNDT
  • Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising Tau
    Patent number: 10066010
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 4, 2018
    Assignees: AC IMMUNE S.A., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system
    Patent number: 9701660
    Abstract: The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: July 11, 2017
    Assignee: AC Immune S.A.
    Inventors: Heiko Kroth, Wolfgang Froestl, Andrea Pfeifer, Andreas Muhs
  • Method for preparing liposome-based constructs
    Patent number: 9687447
    Abstract: The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic use in the treatment of diseases and disorders, which are caused by or associated with proteopathy such as Alzheimer's Disease.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: June 27, 2017
    Assignee: AC Immune S.A.
    Inventors: Pedro Reis, David Hickman, Maria Pihlgren Bosch, Andreas Muhs, Andrea Pfeifer
  • Humanized tau antibody
    Patent number: 9657091
    Abstract: The present invention provides methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to humanized antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 23, 2017
    Assignees: AC Immune S.A., Katholieke Universiteit Leuven
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • PHOSPHOSPECIFIC ANTIBODIES RECOGNISING TAU
    Publication number: 20170137502
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Application
    Filed: October 28, 2016
    Publication date: May 18, 2017
    Applicants: AC IMMUNE S.A., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • Anti-tau antibodies and methods of use
    Patent number: 9598485
    Abstract: The present invention relates to anti-Tau antibodies, such as antibodies that bind to a phosphorylated epitope on human Tau protein with high specificity and/or affinity, and methods of using the same.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 21, 2017
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Gai Ayalon, Danielle Marie Di Cara, Isidro Hotzel, Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson
  • Polynucleotides encoding anti-amyloid beta monoclonal antibodies
    Patent number: 9585956
    Abstract: The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: March 7, 2017
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Phosphospecific antibodies recognising tau
    Patent number: 9540434
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 10, 2017
    Assignees: AC IMMUNE S.A., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • HUMANIZED ANTIBODY
    Publication number: 20160272699
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: October 28, 2015
    Publication date: September 22, 2016
    Applicants: GENENTECH, INC., AC IMMUNE S.A.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Humanized Antibody
    Publication number: 20160244514
    Abstract: The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.
    Type: Application
    Filed: December 22, 2015
    Publication date: August 25, 2016
    Applicants: Genentech, Inc., AC Immune S.A.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
    Patent number: 9403902
    Abstract: The present invention provides methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of amyloid-beta proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly those ocular diseases associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: August 2, 2016
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts